Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability

Current Nanoscience

Volumn 9, Issue 1, 2013, Pages 26-34

  Sood, Sumeet ^a   Jawahar, Natarajan ^a   Jain, Kunal ^a   Gowthamarajan, Kuppusamy ^a   Meyyanathan, Subramania Nainar ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Bioavailability; Cationic; Microemulsion; Olanzapine; Oral delivery; Solid lipid nanoparticles

Indexed keywords

BIOCHEMISTRY; METABOLISM; MICROEMULSIONS; NANOPARTICLES; STEARIC ACID;

BIOAVAILABILITY; CATIONIC; OLANZAPINE; ORAL DELIVERY; SOLID LIPID NANOPARTICLE (SLN);

DRUG DELIVERY;

OCTADECYLAMINE; OLANZAPINE; SOLID LIPID NANOPARTICLE; SURFACTANT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; FIRST PASS EFFECT; LYMPH VESSEL; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MELTING POINT; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

EID: 84875962619     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/1573413711309010007     Document Type: Article

References (35)

1. Mehnert, W.; Mäder, K. Solid lipid nanoparticles Production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47, 165-196.
2. Müller, R.H.; Runge, S.; Ravelli, V.; Mehnert, W.; Thünemann, A.F.; Souto, E.B. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm., 2006, 317, 82-89.
3. Barratt, G.M. Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today, 2000, 3, 163-171.
4. Forrest, M.L.; Kwon G.S. Clinical developments in drug delivery nanotechnology. Adv. Drug Deliv. Rev., 2008, 60, 861-862.
5. Bhana, N.; Perry, C.M. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs, 2001, 15, 871-904.
6. Mattiuz, E.; Franklin, R.; Gillespie, T.; Murphy, A.; Bernstein, J.; Chiu, A.; Hotten, T.; Kassahun, K. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab. Dispos., 1997, 25(5), 573-583.
7. Suresh, G.; Manjunath, K.; Venkateswarlu, V.; Satyanarayana, V. Preparation, Characterization, and In vitro and In vivo evaluation of Lovastatin Solid Lipid nanoparticles, AAPS Pharm. Sci. Tech., 2007, 8(1), Article 24:E1-E9.
8. Paliwal, R., Rai, S., Vaidya, B., Khatri, K., Goyal, A.K., Mishra, N., Mehta, A.; Vyas, S.P. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 2009, 5, 184-191.
9. Alam, M.I.; Baboota, S.; Ahuja, A.; Ali, M.; Ali, J.; Sahni, J.K. Nanostructured Lipid Carrier Containing CNS Acting Drug: Formulation, Optimization and Evaluation. Curr. Nanosci., 2011, 7(6), 1014-1027.
10. Mustafa G.; Baboota, S.; Ahuja, A.; Ali, J. Formulation Development of Chitosan Coated Intra Nasal Ropinirole Nanoemulsion for Better Management Option of Parkinson: An In vitro Ex Vivo Evaluation. Curr. Nanosci., 2012, 8(3), 348-360.
11. Date, A.A.; Joshi, M.D.; Patravale, V.B. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 505-521.
12. Blasi, P; Giovagnoli, S; Schoubben, A; Ricci, M; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59, 454-477.
13. Chakraborty, S; Shukla, D; Mishra, B; Singh, S. Lipid- An emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Bio-pharm., 2009, 73, 1-15.
14. Vivek, K; Reddy, H; Murthy, R.S.R. Investigations on the effect of lipid matrix on drug entrapment, In vitro release, and physical stability of olanzap-ine-loaded solid lipid nanoparticles. AAPS Pharm. Sci. Tech., 2007, 8(4), Article 83:E1-E9.
15. Cavalli, R; Caputo, O; Carlotti, M.E.; Trotta, M.; Scarnecchia, C., Gasco, M.R. Sterilization and freeze drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm., 1997, 148, 47-54.
16. Ye, J.; Wang, Q.; Zhou, X.; Zhang, N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm., 2008, 352, 273-279.
17. Luo, Y.F.; Chen, D. W.; Ren, L.X.; Zhao, X.L.; Qin, J. Solid lipid nanoparti-cles for enhancing vinpocetine's oral bioavailability. J. Control. Release, 2006, 114, 53-59.
18. Kumar, V.V.; Chandrasekar, D.; Ramakrishna, S.; Kishan, V.; Rao, Y.M.; Diwan, P.V. Development and evaluation of Nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacoki-netics. Int. J. Pharm., 2007, 335, 167-175.
19. Costa, P.; Lobo, J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci., 2001, 13, 123-133.
20. Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery- a review of the state of the art. Eur. J. Pharm. Bio-pharm., 2000, 50, 161-177.
21. Venkateswarlu, V.; Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release, 2004, 95, 627-638.
22. Singh, S.K.; Srinivasan, K.K.; Gowthamarajan, K.; Singare, D.S.; Prakash, D.; Gaikwad, N.B. Investigation of preparation parameters of nanosuspen-sion by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur. J. Pharm. Biopharm., 2011, 78, 441-446.
23. Manjunath, K.; Venkateswarlu, V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and in-traduodenal administration. J. Control. Release, 2005, 107, 215-228.
24. Cavalli, R.; Aquilano, D.; Carlotti, M.E.; Gasco, M.R. Study by X-ray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles. Eur. J. Pharm. Biopharm., 1995, 41, 329-333.
25. zur Mühlen, A.; Schwarz, C.; Mehenert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanisms. Eur. J. Pharm. Biopharm., 1998, 45, 149-155.
26. TM) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47, 125-132.
27. Jenning, V.; Thunemann, A.F.; Gohla, S.H. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm., 2000, 199, 167-177.
28. Hou, D.Z.; Xie, C.S.; Huang, K.J.; Zhu, C.H. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials, 2003, 24, 1781-1785.
29. Duchêne, D.; Ponchel,G. Bioadhesion of solid oral dosage forms, why and how? Eur. J. Pharm. Biopharm., 1997, 44, 15-23.
30. El-Shabouri, M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int. J. Pharm., 2002, 249, 101-108.
31. Porter, C.J.H.; Pouton, C.W.; Cuine, J.F.; Charman, W.N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug. Deliv. Rev., 2008, 60, 673-691.
32. Olbrich, C.; Müller, R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 1999, 180, 31-39.
33. Olbrich, C.; Kayser, O.; Müller, R.H. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int. J. Pharm., 2002, 237, 119-128.
34. Zhang, Y.C.; Benet, L.Z. The gut as a barrier to drug absorption combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 2001, 40(3), 159-168.
35. Seeballuck, F.; Ashford, M.B.; O'Driscoll, C.M. The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm. Res., 2003, 20(7), 1085-1092.